FosA8-producing E. coli ST131: clinical cases in Italy, February 2023
Jazyk angličtina Země Švédsko Médium print
Typ dokumentu časopisecké články, kazuistiky
PubMed
38785090
PubMed Central
PMC11128740
DOI
10.2807/1560-7917.es.2024.29.21.2400276
Knihovny.cz E-zdroje
- Klíčová slova
- E. coli ST131, FosA8, Fosfomycin, Fosfomycin resistance,,
- MeSH
- antibakteriální látky * farmakologie terapeutické užití MeSH
- bakteriální léková rezistence MeSH
- beta-laktamasy genetika metabolismus MeSH
- Escherichia coli * izolace a purifikace genetika účinky léků MeSH
- fosfomycin farmakologie terapeutické užití MeSH
- infekce vyvolané Escherichia coli * mikrobiologie epidemiologie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- multilokusová sekvenční typizace MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
- Geografické názvy
- Itálie epidemiologie MeSH
- Názvy látek
- antibakteriální látky * MeSH
- beta-laktamasy MeSH
- fosfomycin MeSH
Fosfomycin-resistant FosA8-producing Enterobacterales are uncommon strains with extremely low incidence in Europe, based on only three reports in the literature. We detected FosA8-producing Escherichia coli ST131 in clinical isolates from two patients admitted in February 2023 to a rehabilitation unit in Italy. The occurrence of rare fosA-like genes in the high-risk clone ST131 is of clinical relevance. The dissemination of FosA-producing E. coli, although still at low levels, should be continuously monitored.
Biomedical Center Faculty of Medicine Charles University Pilsen Czechia
Microbiology Unit IRCCS Istituti Clinici Scientifici Maugeri Pavia Italy
Specialization School of Microbiology and Virology University of Pavia Pavia Italy
Zobrazit více v PubMed
Falagas ME, Athanasaki F, Voulgaris GL, Triarides NA, Vardakas KZ. Resistance to fosfomycin: mechanisms, frequency and clinical consequences. Int J Antimicrob Agents. 2019;53(1):22-8. 10.1016/j.ijantimicag.2018.09.013 PubMed DOI
Mattioni Marchetti V, Hrabak J, Bitar I. Fosfomycin resistance mechanisms in Enterobacterales: an increasing threat. Front Cell Infect Microbiol. 2023;13:1178547. 10.3389/fcimb.2023.1178547 PubMed DOI PMC
European Committee on Antimicrobial Susceptibility Testing (EUCAST). The 13.0 versions of breakpoints, dosing and QC (2023) published. Växjö: EUCAST; 2023. Available from: https://www.eucast.org/eucast_news/news_singleview?tx_ttnews%5Btt_news%5D=518&cHash=2509b0db92646dffba041406dcc9f20c
Mattioni Marchetti V, Kraftova L, Finianos M, Sourenian T, Hrabak J, Bitar I. Polyclonal spread of fosfomycin resistance among carbapenemase-producing members of the Enterobacterales in the Czech Republic. Microbiol Spectr. 2023;11(3):e0009523. 10.1128/spectrum.00095-23 PubMed DOI PMC
Carattoli A, Zankari E, Garcia-Fernandez A, Volby Larsen M, Lund O, Villa L, et al. PlasmidFinder and pMLST: in silico detection and typing of plasmids. Antimicrob Agents Chemother. 2014;58(7):3895-903. 10.1128/AAC.02412-14 PubMed DOI PMC
Poirel L, Vuillemin X, Kieffer N, Mueller L, Descombes MC, Nordmann P. Identification of FosA8, a plasmid-encoded fosfomycin resistance determinant from Escherichia coli, and its origin in Leclercia adecarboxylata. Antimicrob Agents Chemother. 2019;63(11):e01403-19. 10.1128/AAC.01403-19 PubMed DOI PMC
Piazza A, Corbella M, Mattioni Marchetti V, Merla C, Mileto I, Kuka A, et al. Clinical isolates of ST131 blaOXA-244-positive Escherichia coli, Italy, December 2022 to July 2023. Euro Surveill. 2024;29(8):2400073. 10.2807/1560-7917.ES.2024.29.8.2400073 PubMed DOI PMC
Tanrıverdi Çaycı Y, Hacıeminoğlu Ülker K, Karacan Temür G, Güney DB, Ertokatlı M, Birinci A. Escherichia coli İzolatlarında O25b-ST131 Klonu Sıklığı ile Karbapenem ve Fosfomisin Direnç Genlerinin Varlığının Araştırılması: Escherichia coli O25b-ST131 İzolatlarında Türkiye’den İlk fosA3 Tespiti. [Investigation of O25b-ST131 Clone Frequency and Presence of Carbapenem and Fosfomycin Resistance Genes in Escherichia coli Isolates: First Detection of fosA3 from Escherichia coli O25bSTf131 Clone from Türkiye]. Mikrobiyol Bul. 2023;57(3):454-62. Turkish. 10.5578/mb.20239937 PubMed DOI
Shi J, Zhu H, Liu C, Xie H, Li C, Cao X, et al. Epidemiological and genomic characteristics of global mcr-positive Escherichia coli isolates. Front Microbiol. 2023;13:1105401. 10.3389/fmicb.2022.1105401 PubMed DOI PMC
Hameed MF, Chen Y, Bilal H, Khan S, Ge H, Xiaofang C, et al. The Co-occurrence of mcr-3 and fosA3 in IncP plasmid in ST131 Escherichia coli: A novel case. J Infect Dev Ctries. 2022;16(4):622-9. 10.3855/jidc.15943 PubMed DOI
Milner KA, Bay DC, Alexander D, Walkty A, Karlowsky JA, Mulvey MR, et al. Identification and characterization of a novel FosA7 Member from fosfomycin-resistant Escherichia coli clinical isolates from Canadian hospitals. Antimicrob Agents Chemother. 2020;65(1):e00865-20. 10.1128/AAC.00865-20 PubMed DOI PMC
Findlay J, Sierra R, Raro OHF, Aires-de-Sousa M, Andrey DO, Nordmann P. Plasmid-mediated fosfomycin resistance in Escherichia coli isolates of worldwide origin. J Glob Antimicrob Resist. 2023;35:137-42. 10.1016/j.jgar.2023.09.003 PubMed DOI
Sullivan MJ, Petty NK, Beatson SA. Easyfig: a genome comparison visualizer. Bioinformatics. 2011;27(7):1009-10. 10.1093/bioinformatics/btr039 PubMed DOI PMC
FosA3 emerging in clinical carbapenemase-producing C. freundii